Rezultaty - Andrew J. Souers

  • Rezultaty 1 - 17 Rezultaty od 17
Redukuj rezultaty
  1. 1
    Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

    Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) od Darren C. Phillips, Yu Xiao, Lloyd T. Lam, Elizabeth Litvinovich, Lisa Roberts-Rapp, Andrew J. Souers, Joel D. Leverson

    Wydane 2015
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  2. 2
    Acquired resistance to venetoclax (ABT-199) in<i>t(14;18)</i>positive lymphoma cells

    Acquired resistance to venetoclax (ABT-199) in<i>t(14;18)</i>positive lymphoma cells od Juraj Bodo, Xiaoxian Zhao, Lisa Durkin, Andrew J. Souers, Darren C. Phillips, Mitchell R. Smith, Eric D. Hsi

    Wydane 2016
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  3. 3
    Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

    Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax od Joel D. Leverson, Deepak Sampath, Andrew J. Souers, Saul H. Rosenberg, Wayne J. Fairbrother, Martine Amiot, Marina Konopleva, Anthony Letai

    Wydane 2017
    Dokumenty pełnotekstowe
    Revisão
    Dodaj do listy ulubionych książek
    Zapisane w:
  4. 4
    Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer

    Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer od Haichao Zhang, John Xue, Paul Hessler, Stephen K. Tahir, Jun Chen, Sha Jin, Andrew J. Souers, Joel D. Leverson, Lloyd T. Lam

    Wydane 2015
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  5. 5
    The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

    The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma od Cyrille Touzeau, Christelle Dousset, Steven Le Gouill, Deepak Sampath, Joel D. Leverson, Andrew J. Souers, Sophie Maïga, Marie C. Béné, Philippe Moreau, Catherine Pellat‐Deceunynck, Martine Amiot

    Wydane 2013
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Carta
    Dodaj do listy ulubionych książek
    Zapisane w:
  6. 6
    Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X<sub>L</sub>–BAX interaction

    Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X<sub>L</sub>–BAX interaction od Tareq Saleh, Valerie J. Carpenter, Liliya Tyutyunyk‐Massey, Graeme Murray, Joel D. Leverson, Andrew J. Souers, Moureq R. Alotaibi, Anthony C. Faber, Jason Reed, Hisashi Harada, David A. Gewirtz

    Wydane 2020
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  7. 7
    MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

    MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor od Yu Xiao, Paul Nimmer, George S. Sheppard, Milan Bruncko, Paul Hessler, Xin Lü, Lisa Roberts-Rapp, William N. Pappano, Steven W. Elmore, Andrew J. Souers, Joel D. Leverson, Darren C. Phillips

    Wydane 2015
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  8. 8
    Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia

    Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia od Brenda Chyla, Naval Daver, Kelly Doyle, Evelyn McKeegan, Xin Huang, Vivian Ruvolo, Zixing Wang, Ken Chen, Andrew J. Souers, Joel D. Leverson, Jalaja Potluri, Erwin R. Boghaert, Anahita Bhathena, Marina Konopleva, Relja Popovic

    Wydane 2018
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Carta
    Dodaj do listy ulubionych książek
    Zapisane w:
  9. 9
    Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma

    Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma od Timothy L. Lochmann, Krista M. Powell, Jungoh Ham, Konstantinos V. Floros, Daniel A.R. Heisey, Richard Kurupi, Marissa L. Calbert, Maninderjit S. Ghotra, Patricia Greninger, Mikhail G. Dozmorov, Madhu Gowda, Andrew J. Souers, C. Patrick Reynolds, Cyril H. Benes, Anthony C. Faber

    Wydane 2018
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  10. 10
    Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

    Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models od Elizabeth A. Punnoose, Joel D. Leverson, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont, Nguyen Tan, A. Young, Michael J. Mitten, Ellen Ingalla, Walter C. Darbonne, Anatol Oleksijew, Paul Tapang, Yue Peng, Jason Oeh, Leslie Lee, Sophie Maïga, Wayne J. Fairbrother, Martine Amiot, Andrew J. Souers, Deepak Sampath

    Wydane 2016
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  11. 11
    Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression

    Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression od Timothy L. Lochmann, Konstantinos V. Floros, Mitra Naseri, Krista M. Powell, Wade Cook, Ryan J. March, Giovanna T. Stein, Patricia Greninger, Yuki Kato Maves, Laura R. Saunders, Scott J. Dylla, Carlotta Costa, Sosipatros A. Boikos, Joel D. Leverson, Andrew J. Souers, Geoffrey W. Krystal, Hisashi Harada, Cyril H. Benes, Anthony C. Faber

    Wydane 2017
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  12. 12
    A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

    A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies od Darren C. Phillips, Sha Jin, Gareth P. Gregory, Qi Zhang, John Xue, Xiaoxian Zhao, Jun Chen, Yunsong Tong, Haichao Zhang, Morey L. Smith, Stephen K. Tahir, Rick Clark, Thomas D. Penning, Jennifer R. Devlin, Jake Shortt, Eric D. Hsi, Daniel H. Albert, Marina Konopleva, Ricky W. Johnstone, Joel D. Leverson, Andrew J. Souers

    Wydane 2019
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  13. 13
    Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

    Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target od Kyung-A Song, Yasuyuki Hosono, Crystal Turner, Sheeba Jacob, Timothy L. Lochmann, Yoshiko Murakami, Neha U. Patel, Jungoh Ham, Bin Hu, Krista M. Powell, Colin M. Coon, Brad E. Windle, Yuko Oya, Jennifer E. Koblinski, Hisashi Harada, Joel D. Leverson, Andrew J. Souers, Aaron N. Hata, Sosipatros A. Boikos, Yasushi Yatabe, Hiromichi Ebi, Anthony C. Faber

    Wydane 2018
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  14. 14
    Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

    Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) od Joel D. Leverson, H Zhang, J Chen, Sajid Khan Tahir, Darren C. Phillips, John Xue, Paul Nimmer, Sha Jin, Morey L. Smith, Yu Xiao, Peter Kovar, Atsushi Tanaka, Milan Bruncko, George S. Sheppard, Longcheng Wang, Sarah Gierke, Lorn Kategaya, Daniel J. Anderson, Chihunt Wong, Jeffrey Eastham‐Anderson, Mary J. C. Ludlam, Deepak Sampath, Wayne J. Fairbrother, Ingrid E. Wertz, S.H. Rosenberg, Christin Tse, Steven W. Elmore, Andrew J. Souers

    Wydane 2015
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  15. 15
    Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

    Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients od Junichiro Yuda, Christine Will, Darren C. Phillips, Linu Abraham, Cory Alvey, Abraham Avigdor, Wayne R. Buck, Lauren M. Besenhofer, Erwin R. Boghaert, Cheng Dong, Dan Cojocari, Kelly Doyle, Terkel Hansen, Kevin Y. Huang, Eric F. Johnson, Andrew S. Judd, Russell A. Judge, J. Cory Kalvass, Aaron Kunzer, Lloyd T. Lam, Rachel Li, Ruth L. Martin, Anthony Mastracchio, Mike Mitten, Adam M. Petrich, Jin Wang, James E. Ward, Haichao Zhang, Xilu Wang, Johannes Wolff, Katherine M. Bell‐McGuinn, Andrew J. Souers

    Wydane 2023
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  16. 16
    Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> Inhibitor

    Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> Inhibitor od Le Wang, George Doherty, Andrew S. Judd, Zhi‐Fu Tao, Terkel Hansen, Robin R. Frey, Xiaohong Song, Milan Bruncko, Aaron Kunzer, Xilu Wang, Michael Wendt, John A. Flygare, Nathaniel D. Catron, Russell A. Judge, Chang H. Park, Shashank Shekhar, Darren C. Phillips, Paul Nimmer, Morey L. Smith, Stephen K. Tahir, Xiao Yu, John Xue, Haichao Zhang, Phuong N Le, Michael J. Mitten, Erwin R. Boghaert, Wenqing Gao, Peter Kovar, Edna F. Choo, Dolores Diaz, Wayne J. Fairbrother, Steven W. Elmore, Deepak Sampath, Joel D. Leverson, Andrew J. Souers

    Wydane 2020
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  17. 17
    Discovery of a Potent and Selective BCL-X<sub>L</sub> Inhibitor with <i>in Vivo</i> Activity

    Discovery of a Potent and Selective BCL-X<sub>L</sub> Inhibitor with <i>in Vivo</i> Activity od Zhi‐Fu Tao, Lisa Hasvold, Le Wang, Xilu Wang, Andrew M. Petros, Chang H. Park, Erwin R. Boghaert, Nathaniel D. Catron, Jun Chen, Peter M. Colman, Peter E. Czabotar, Kurt Deshayes, Wayne J. Fairbrother, John A. Flygare, S.G. Hymowitz, Sha Jin, Russell A. Judge, Michael F. T. Koehler, Peter Kovar, Guillaume Lessène, Michael J. Mitten, Chudi Ndubaku, Paul Nimmer, Hans E. Purkey, Anatol Oleksijew, Darren C. Phillips, Brad E. Sleebs, Brian J. Smith, Morey L. Smith, Stephen K. Tahir, Keith G. Watson, Xiao Yu, John Xue, Haichao Zhang, Kerry Zobel, Saul H. Rosenberg, Chris Tse, Joel D. Leverson, Steven W. Elmore, Andrew J. Souers

    Wydane 2014
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:

Narzędzie wyszukiwania: